跳至主要内容
临床试验/NCT01078558
NCT01078558已完成不适用

A Five Year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis or Psoriatic Arthritis Who Are Treated With HUMIRA (Adalimumab)

AbbVie (prior sponsor, Abbott)0 个研究点目标入组 5,940 人开始时间: 2004年5月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
5,940
主要终点
Change From Baseline in Swollen Joints Over Time

研究概览

简要总结

This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with ongoing HUMIRA (adalimumab) treatment who have been prescribed HUMIRA (adalimumab) within local reimbursement guidelines.
  • Patients must be willing to consent to data being collected and provided to Abbott Laboratories.

排除标准

  • Contraindications according to the summary of product characteristics.
  • Patients who are actually followed in the ReAlise registry (M03-634 NCT00234884).

结局指标

主要结局

Change From Baseline in Swollen Joints Over Time

时间窗: Baseline, Months 3, 6, 12, 24, 60

A total of 28 joints were assessed for swelling.

Change From Baseline in Patient's Numerical Rating Scale Over Time: Oligoarticular PsA Participants

时间窗: Baseline, Months 3, 6, 12, 24, 60

Participants used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.

Change From Baseline in Physician's Assessment of Disease Activity Over Time

时间窗: Baseline, Months 3, 6, 12, 24, 60

Physician's assessment of disease activity is measured on a visual analogue scale (VAS) from 0 to 100, with the highest values indicating the worst disease activity.

Inflammatory Parameter: Change From Baseline in CRP Over Time

时间窗: Baseline, Months 3, 6, 12, 24, 60

Change From Baseline in DAS28 Over Time: RA Participants

时间窗: Baseline, Months 3, 6, 12, 24, 60

The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in Tender Joints Over Time

时间窗: Baseline, Months 3, 6, 12, 24, 60

A total of 28 joints were assessed for tenderness.

Inflammatory Parameter: Change From Baseline in ESR Over Time

时间窗: Baseline, Months 3, 6, 12, 24, 60

Physical Function: Change From Baseline in HAQ% Over Time

时间窗: Baseline, Months 3, 6, 12, 24, 60

The HAQ score measures quality of life in terms of physical function and consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past 7 days using the following responses: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). In the classical HAQ questionnaire, the potential maximum score (60) indicates the most severe disability and the minimum score (0) indicates no disability. The HAQ% is a typical 'Belgian scoring method,' where the actual total score on 60 is converted to a percentage. The HAQ% is performed by all Belgian rheumatologists and is required for obtaining reimbursement.

DAS28 Category Over Time: RA Participants

时间窗: Baseline, Months 3, 6, 12, 24, 60

The DAS28 score includes 28 tender joint counts, 28 swollen joint counts, CRP/ESR, and participant's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Change From Baseline in BASDAI Over Time: AS Participants

时间窗: Baseline, Months 3, 6, 12, 24, 60

BASDAI score measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness, and is calculated using a questionnaire with 6 questions that the participant completes by marking answers on a 10-centimeter visual analog scale with responses that range from 0 (none) to 10 (very severe). The final BASDAI score ranges from 0 to 10 with higher score indicating more severe symptoms.

BSA With PsA Over Time: PsA Participants

时间窗: Baseline, Months 3, 6, 12, 24, 60

Change From Baseline in Physician's Numerical Rating Scale Over Time: Oligoarticular PsA Participants

时间窗: Baseline, Months 3, 6, 12, 24, 60

Physicians used a Numerical Rating Scale of 0 to 10 to assess the most important joint, where 0=no disease activity during the previous days and 10=maximal activity during the previous days.

Number of Participants With Adverse Events (AEs) Serious AEs (SAEs), and AEs Leading to Study Drug Discontinuation

时间窗: up to 60 months

An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. An SAE is an AE that results in death, is life-threatening, results in or prolongs hospitalization, results in congenital anomaly, persistent or significant disability/incapacity, spontaneous or elective abortion, or requires intervention to prevent a serious outcome. The protocol required all SAEs to be actively solicited. Non-serious events were not to be actively solicited, and any non-serious AEs were to be collected as spontaneous reports if AbbVie was notified.

次要结局

未报告次要终点

研究者

发起方
AbbVie (prior sponsor, Abbott)
申办方类型
Industry
责任方
Sponsor

相似试验